Ahn Ki Jung, Park Jisun, Choi Yunseon
Department of Radiation Oncology, Inje University Busan Paik Hospital, Busan, Korea.
Department of Nuclear Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Radiat Oncol J. 2017 Dec;35(4):332-339. doi: 10.3857/roj.2017.00416. Epub 2017 Dec 15.
This study aimed to evaluate the prognostic effects of lymphovascular invasion (LVI) in triple-negative breast cancer (TNBC) patients who underwent surgical resection.
A total of 63 non-metastatic TNBC patients who underwent surgical resection were retrospectively investigated from 2007 to 2016 in Inje University Busan Paik Hospital. Pathological tests revealed that 12 patients (19.0%) had LVI. Approximately 61.9% (n = 39) of the patients' samples stained positive for p53. Additional chemotherapy and radiotherapy (RT) were performed in 53 (84.1%) and 47 (74.6%) patients, respectively.
The median follow-up period was 39.5 months (range, 5.9 to 123.0 months). The pathological T stage (p = 0.008), N stage (p = 0.014), and p53 positivity (p = 0.044) were associated with LVI. Overall, the 3-year disease-free survival (DFS) rate and overall survival (OS) rate were 85.4% and 90.2%, respectively. Ten patients (15.9%) experienced relapse. LVI (n = 12) was associated with relapses (p = 0.016). p53 positivity was correlated with poor DFS (p = 0.048). Furthermore, LVI was related to poor DFS (p = 0.011) and OS (p = 0.001) and considered as an independent prognostic factor for DFS (p = 0.039). The 3-year DFS of patients with LVI (n = 12) was only 58.3%. Adjuvant RT minimized the negative prognostic effect of LVI on DFS (p = 0.068 [with RT] vs. p = 0.011 [without RT]).
LVI was related to the detrimental effects of disease progression and survival of TNBC patients. Thus, a more effective treatment strategy is needed for TNBC patients with LVI.
本研究旨在评估接受手术切除的三阴性乳腺癌(TNBC)患者中淋巴管侵犯(LVI)的预后影响。
回顾性调查了2007年至2016年在仁济大学釜山白医院接受手术切除的63例非转移性TNBC患者。病理检查显示,12例患者(19.0%)存在LVI。约61.9%(n = 39)的患者样本p53染色呈阳性。分别有53例(84.1%)和47例(74.6%)患者接受了辅助化疗和放疗。
中位随访期为39.5个月(范围为5.9至123.0个月)。病理T分期(p = 0.008)、N分期(p = 0.014)和p53阳性(p = 0.044)与LVI相关。总体而言,3年无病生存率(DFS)和总生存率(OS)分别为85.4%和90.2%。10例患者(15.9%)出现复发。LVI(n = 12)与复发相关(p = 0.016)。p53阳性与DFS较差相关(p = 0.048)。此外,LVI与DFS较差(p = 0.011)和OS较差(p = 0.001)相关,并被视为DFS的独立预后因素(p = 0.039)。LVI患者(n = 12)的3年DFS仅为58.3%。辅助放疗将LVI对DFS的负面预后影响降至最低(p = 0.068[放疗组]对p = 0.011[未放疗组])。
LVI与TNBC患者疾病进展和生存的不良影响相关。因此,对于存在LVI的TNBC患者需要更有效的治疗策略。